PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.
Scott S. Tykodi
Research Funding - Bristol-Myers Squibb
Julie R. Brahmer
No relevant relationships to disclose
Wen-Jen Hwu
Research Funding - Bristol-Myers Squibb
Laura Q. Chow
Research Funding - Bristol-Myers Squibb
Suzanne Louise Topalian
Consultant or Advisory Role - Amplimmune (I); Bristol-Myers Squibb (B,U)
Research Funding - Bristol-Myers Squibb
Patrick Hwu
No relevant relationships to disclose
Kunle Odunsi
No relevant relationships to disclose
Luis H. Camacho
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
John S Kauh
No relevant relationships to disclose
Henry Clement Pitot
No relevant relationships to disclose
Omid Hamid
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Drew M. Pardoll
Consultant or Advisory Role - Amplimmune; Bristol-Myers Squibb (U)
Shruti Agrawal
Employment or Leadership Position - Bristol-Myers Squibb
Susan Parker
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Stacie Goldberg
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jon Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb